The $HCWB Shell Game: How Management Inflated EPS, Conceded Core IP to Trimmune JV, and Staged a 58% Retail Cramdown

Fellow Investors, if you are holding or tracking HCW Biologics (**$HCWB**), you need to look at the recent sequencing of SEC filings (Form S-1, 8-K, and Schedule 14A). There is an explicit, multi-layered asset-shifting and market-suppression scheme under way that closely replicates the **Altor BioScience** corporate misconduct patterns litigated in 2017 under the same executive block—CEO **Dr. Hing C. Wong**, CSO **Dr. Peter Rhode**, and Senior VP **Lee D. Flowers**.

**1. Non-Dilutive CAR-T Revenue Hiding (The Akron Deception)**
On September 4, 2026, the Board executed an Exclusive Distribution Agreement with **Akron Biotech** for its **HCW11-006** multi-cytokine fusion molecule as an *ex vivo* reagent for CAR-T cell manufacturing. This contract guarantees upfront milestone advances ($200k at closing, $100k post-supply, and $100k on consecutive anniversaries) alongside recurring quarterly technical fees and pre-payment commitments. This cash-flow completely invalidates any legitimate corporate necessity for emergency equity dilution. Yet, the Board deliberately withheld this positive disclosure to launch the predatory Schedule 14A dilution Proxy first on September 8, intentionally crushing the price to scare retail ("shaking out the paper") while protecting low-strike insider accumulation thresholds.

**2. Fraudulent Asset Stripping under SEC Exhibit 10.40 Section 9.2.2**
The public US listed vehicle has been left exclusively burdened with the astronomical financial liabilities of capital-intensive clinical trials—specifically the second-generation T-cell engager program **HCW11-08B** and **HCW11-040**—under an accumulated deficit of over **$108.5 million** and a active **"Going Concern" bankruptcy warning**. Meanwhile, the core commercial upside for **HCW11-006** (*in vivo*) and the blockbuster Alopecia drug (**HCW9302**) has been transferred to Beijing Trimmune Biotech for pennies. Under **Section 9.2.2 of SEC Exhibit 10.40**, these assets are structurally sheltered from US liquidation in the event of bankruptcy, protecting insiders while public holders absorb 100% of the operational losses.

**3. The Accounting Distortion and 60%+ Majority Abuse**
On August 14, 2026, the Audit Committee filed a Form 8-K (Item 4.02) admitting a **material weakness in internal controls**, which **artificially overstated EPS by $0.80 to $2.19 per share** under ASC 260. They used this distorted premium to execute cheap private placements at $2.585. Now, Proposal Two seeks a **2,500,000-share Special Reserve (111.7% of the total public outstanding float)** designed to grant sequential 20% option tranches to insiders upon the stock price sustaining escalating milestones of **$5, $10, $20, and $40 for 20 consecutive trading days**. Because executive insiders and affiliated hedge funds control **in excess of 60% of the total voting power**, this upcoming October 27 vote is a mathematically predetermined corporate sham.

**Action Plan:** File your formal objections, request your 16-digit control numbers from your brokers, vote **AGAINST** on both proposals, and forward this evidence directly to specialized securities litigation firms like Pomerantz Law (`newaction@pomlaw.com`) and The Rosen Law Firm (`case@rosenlegal.com`).